Overcoming platinum resistance in ovarian carcinoma

Abstract

Importance of the field-Ovarian cancer remains a deadly malignancy because most patients develop recurrent disease that is resistant to chemotherapy, including platinum. Because response rates for current treatment regimens are relatively similar and unfortunately low, no standard chemotherapy for platinum-resistant ovarian cancer exists. What the reader will gain-Gemcitabine was the most common drug used in clinical trials reporting higher response rates, ≥+1 SD of overall response rate (5 out of 8). Gemcitabine-based combination therapy showed an average response rate of 27.2% (95%CI 22.4-32.0). Combination of gemcitabine and pegylated liposomal doxorubicin (PLD) was the most common regimen (n=3) and was associated with possible additive effects in platinum-resistant ovarian cancer patients: response rate, gemcitabine alone 6.1%, PLD alone 19.8%, and gemcitabine with PLD 28.7% (95% CI 20.4-37.0), respectively. Areas covered in this reviewTake home message-Analysis of recent clinical trials showed that gemcitabine-based combination chemotherapy was associated with the highest anti-tumor effects in platinum-resistant ovarian cancer patients during the study period.

Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer

“…However, virtually all patients eventually develop secondary resistance to platinum based agents and compounds used for second or third line treatment. Other substances display substantially less anti-cancer activity as compared to platinum [5]. There is a definite clinical need to develop new treatment strategies to overcome platinum resistance.…”

Immune escape of AKT overexpressing ovarian cancer cells

“…However, virtually all patients eventually develop secondary resistance to platinum based agents and compounds used for second-or third-line treatment. Other substances display substantially less anticancer activity as compared to platinum (4). There is a definite clinical need to develop new treatment strategies to overcome platinum resistance.…”

Long-Term Pegylated Liposomal Doxorubicin Use and Oromaxillary Squamous Cell Carcinoma in Endometrial Cancer

“…A similar finding was observed in our case experience, suggesting that oromaxillary SCC developing after long-term PLD use may be radiorefractory, a characteristic potentially exacerbated by a history of radiation to the brain. PLD is known to be one of the effective antitumor agents for ovarian cancer and is commonly used after recurrence [3]; hence, further investigation into the long-term adverse effects of PLD treatment is definitively warranted, and setting limitations on the maximum dose of PLD should be taken into consideration. …”